Molecubes Preclinical SPECT Imager

This is a contract result notice, not an open opportunity. Details from the official award data.

The procurement contact named on the official notice.

MDC's current imaging capabilities are limited to PET and CT, which restricts us to PET based tracers.

While PET imaging is a powerful tool, it cannot accommodate a growing range of radioisotopes that are increasingly relevant in theranostic applications.

These include lead 203, lead 212, lutetium 177, and actinium 225, which are essential for both diagnostic and therapeutic purposes.

This limitation has become more pronounced as clinical and research interest in SPECT and CT imaging continues to grow.

SPECT imaging enables biodistribution studies for isotopes that PET cannot support.

This opens up new possibilities for molecular imaging and expands our ability to respond to evolving scientific and clinical needs.

We have a clear opportunity to address this gap by introducing SPECT and CT capability through the phased procurement of the SPECT Cube module, followed by an upgrade to the advanced SPECT Cube 2.0 platform.

This will allow MDC to meet rising diagnostic demand, align with industry standards, and maintain clinical competitiveness.

Free to start. Named contacts come from published notices; the strategy is generated from the buyer’s news, accounts and people.